Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Liabilities (2016 - 2025)

Arcadia Biosciences' Total Liabilities history spans 12 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 67.01% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, down 67.01%, while the annual FY2025 figure was $2.4 million, 67.01% down from the prior year.
  • Total Liabilities reached $2.4 million in Q4 2025 per RKDA's latest filing, down from $3.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $28.1 million in Q2 2021 to a low of $2.4 million in Q4 2025.
  • Average Total Liabilities over 5 years is $9.7 million, with a median of $8.0 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: tumbled 70.7% in 2022, then skyrocketed 60.31% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $12.7 million in 2021, then plummeted by 36.94% to $8.0 million in 2022, then dropped by 12.72% to $7.0 million in 2023, then rose by 4.17% to $7.3 million in 2024, then tumbled by 67.01% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Total Liabilities are $2.4 million (Q4 2025), $3.1 million (Q3 2025), and $3.3 million (Q2 2025).